Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MORF
- Company Morphic Holding, Inc.
- Price $56.99
- Changes Percentage 0.04
- Change 0.02
- Day Low $56.97
- Day High $57
- Year High $57
- Year Low $19.35
- Market Cap $2,862,305,653
- Price Avg 50 EMA (D) $44.96
- Price Avg 200 EMA (D) $33.56
- Exchange NASDAQ
- Volume 1,739,150
- Average Volume 2,453,038
- Open $56.97
- Previous Close $56.97
- EPS -3.83
- PE -14.88
- Earnings Announcement 2024-11-01 00:00:00
- Shares Outstanding $50,224,700
Company brief: MORPHIC HOLDING, INC. (MORF )
- Healthcare
- Biotechnology
- Dr. Praveen P. Tipirneni M.D.
- https://www.morphictx.com
- US
- N/A
- 06-27-2019
- US61775R1059
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.